drugset / Trial / NCT03351855
HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to evaluate the safety and efficacy of IV-infused autologous or allogenic HPV-CTLs.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HPV-CTLs | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | HPV-CTLs | Cell therapy | 4e+06 cells/kg | Intravenous |